Risk Factors Update Summary

• Expectations changed from incurring additional losses to achieving profitability based on commercialization goals and operational initiatives.
• Added mention of AI and machine learning technology risks, potential breaches, and regulatory challenges.
• Total expenses are expected to exceed total revenues in 2024, indicating ongoing financial challenges.
• Increased supply-chain attack frequency and severity, impacting data security and operations.
• The company entered into a $450.0 million Pharmakon Loan Agreement in April 2023.
• Identified a material weakness in internal control over financial reporting, affecting accuracy and investor confidence.
• The company had an outstanding principal balance of $313.5 million under the Pharmakon Loan Agreement as of 2023.
• The company faces risks related to potential government actions, such as a U.S. Government shutdown or geopolitical instability.
• The company's ability to perform obligations under the Pharmakon Loan Agreement may be impacted by various factors.
• Compliance with stringent U.S. and international data protection laws and regulations could impact the company's operations.